Nuvectis Pharma (NVCT) Q1 2026 earnings summary

Executive summary

• Focused on developing precision oncology medicines, with NXP900 as the lead candidate in Phase 1b clinical trials targeting SRC/YES1 kinases for solid tumors, with ongoing enrollment in both monotherapy and combination arms at top US sites.

• Preclinical data presented at AACR 2026 showed synergy of NXP900 with sotorasib in NSCLC models, supporting clinical strategy.

• Preliminary data readout from NXP900 Phase 1b study expected in summer 2026.

• No revenue generated to date; operations funded primarily through equity offerings.

• Accumulated deficit reached $105.7 million as of March 31, 2026.

Financial highlights

• Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million at year-end 2025.

• Net loss for Q1 2026 was $6.1 million, compared to $5.3 million in Q1 2025.

• Research and development expenses increased to $4.1 million (up $0.4 million year-over-year), mainly due to higher manufacturing, compensation, and clinical trial costs.

• General and administrative expenses rose to $2.2 million (up $0.3 million year-over-year), driven by increased professional services and compensation.

• Basic and diluted net loss per share was $0.26, compared to $0.27 in the prior year.

Outlook and guidance

• Existing cash is expected to fund operations for at least 12 months from the reporting date.

• Additional capital will be required to complete clinical trials and pursue commercialization.

• Expenses are anticipated to increase as clinical programs advance and public company costs rise.

• Focus remains on achieving key clinical milestones for NXP900 in 2026 and beyond.

• Preliminary Phase 1b data for NXP900 expected in summer 2026.